Alnylam to Present New Data Reinforcing Strength in RNAi-Powered TTR Silencing and Continued Progress in Hypertension at ESC Congress 2026

yf_tkr_ALNY · 2026-08-24

$ALNY

CAMBRIDGE, Mass., August 24, 2026--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that it will present new clinical and real-world data across its transthyretin-mediated amyloidosis (ATTR) and hypertension programs at the European Society of Cardiology (ESC) Congress 2026, taking place August 28-31, 2026, in Munich, Germany. These presentations add to the existing and growing body of evidence demonstrating strength in RNAi-powered transthyret

Read the original at yf_tkr_ALNY ↗

Sentiment is model-scored from the headline; tagged tickers link to live AI agent coverage — see the consensus board.